Aphria Inc. has announced the completion of its previously announced acquisition of Germany-based pharmaceutical distributor CC Pharma GmbH, thereby strengthening the company’s end-to-end cannabis operations and infrastructure in the European country.
“As one of the most promising medical cannabis markets in the world, Germany is a top strategic priority for Aphria,” CEO Vic Neufeld, says in a statement from the Leamington, Ont.-based global cannabis company.
The acquisition of CC Pharma—which distributes pharmaceutical products, including medical cannabis, to 13,000-plus pharmacies in Germany and throughout Europe—is helping Aphria create “a German and, ultimately, pan-European platform that brings together demand, supply and distribution,” Neufeld continues.
“Access to Aphria’s innovative products creates significant opportunities for CC Pharma’s customers to experience more medical cannabis treatment options,” adds Dr. Manfred Ziegler, managing director of CC Pharma.
The company holds 318 active German national pharmaceutical licences and 692 active EU pharmaceutical licences, as well as